利伐沙班治疗静脉血栓的效果如何？

Cancer patients have a high incidence of venous thromboembolism (VTE), and VTE is also a common cause of death in cancer patients. Clinical treatment guidelines emphasize that drug anticoagulation is the basic treatment for this type of disease. The new oral anticoagulant drug rivaroxaban (Xarelto) is a reversible direct factor How effective is the treatment of venous thrombosis?

In a randomized, double-blind, controlled study, patients were divided into 3 groups. In the first group, 1,107 patients took 20 mg of rivaroxaban (Xarelto), in the second group, 1,127 patients took 10 mg of rivaroxaban (Xarelto), and in the third group, 1,131 patients took 100 mg of aspirin. These patients had completed 6 to 12 months of initial anticoagulant therapy.

After 12 months of continuous use, the recurrence rate of venous thrombosis in the aspirin group was 4.4%. The recurrence rate of the rivaroxaban (Xarelto) 20 mg group and the rivaroxaban 10 mg group was significantly lower than that of the aspirin group. For patients with venous thrombosis who have completed 6 to 12 months of treatment and need to continue treatment and who are clinically balanced, using rivaroxaban 20 mg or rivaroxaban 10 mg as a continuous anticoagulant treatment for venous thromboembolism is more effective than aspirin 100 mg, the recurrence rate is significantly lower than aspirin, and the incidence of bleeding is not increased. It also confirmed the feasibility of low-dose rivaroxaban (Xarelto) (10 mg) in the treatment of venous thromboembolism. From the above test data, it can be seen that the effect of rivaroxaban in treating venous thrombosis is very significant. The successful development of this drug has brought hope to many patients with venous thrombosis.

The above is the introduction about rivaroxaban (Xarelto). If patients have other questions about rivaroxaban, they can consult the medical companion travel service.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: